See more : Tianneng Power International Limited (0819.HK) Income Statement Analysis – Financial Results
Complete financial analysis of iBio, Inc. (IBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LexaGene Holdings Inc. (0V43.L) Income Statement Analysis – Financial Results
- Xeros Technology Group plc (XRTEF) Income Statement Analysis – Financial Results
- Fortune Valley Treasures, Inc. (FVTI) Income Statement Analysis – Financial Results
- Iofina plc (IOF.L) Income Statement Analysis – Financial Results
- Multi Manager Invest Globale Value Aktier (MMIGLVAAKT.CO) Income Statement Analysis – Financial Results
iBio, Inc. (IBIO)
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.00K | 0.00 | 2.38M | 2.37M | 1.64M | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 1.18M | 987.06K | 896.27K |
| Cost of Revenue | 0.00 | 1.11M | 216.00K | 1.46M | 703.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.84K | 485.13K | 445.72K |
| Gross Profit | 225.00K | -1.11M | 2.17M | 909.00K | 935.00K | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 675.77K | 501.93K | 450.55K |
| Gross Profit Ratio | 100.00% | 0.00% | 90.94% | 38.34% | 57.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 57.43% | 50.85% | 50.27% |
| Research & Development | 5.19M | 10.33M | 17.73M | 9.99M | 3.21M | 5.47M | 3.99M | 4.12M | 3.16M | 3.50M | -150.00K | 3.43M | 4.98M | 3.08M | 2.52M | 797.40K | 550.00K | 673.23K |
| General & Administrative | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 1.44M |
| Other Expenses | 0.00 | 0.00 | 13.00K | 12.00K | 10.00K | 16.00K | 19.00K | 25.00K | 21.00K | 32.00K | 45.00K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
| Operating Expenses | 16.86M | 29.34M | 51.86M | 32.02M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 2.60M | 2.37M | 2.12M |
| Cost & Expenses | 16.86M | 29.34M | 52.07M | 33.48M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 3.10M | 2.85M | 2.56M |
| Interest Income | 363.00K | 130.00K | 178.00K | 140.00K | 15.00K | 75.00K | 15.00K | 39.00K | 22.00K | 9.00K | 130.00K | 9.00K | 11.67K | 12.62K | 12.73K | 20.42K | 0.00 | 0.00 |
| Interest Expense | 172.00K | 0.00 | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M | 807.00K | 0.00 | 122.00K | 90.00K | 62.85K | 50.50K | 13.11K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.25M | 1.11M | 3.79M | 2.41M | 2.24M | 1.75M | 1.71M | 1.68M | 940.00K | 363.00K | 361.00K | 338.00K | 329.71K | 376.81K | 337.03K | 283.95K | 245.27K | 322.04K |
| EBITDA | -14.02M | -28.12M | -25.72M | -18.35M | -11.74M | -13.95M | -12.48M | -12.53M | -8.91M | -6.30M | -3.31M | -5.86M | -5.35M | -9.28M | -5.73M | -1.62M | -1.62M | -1.34M |
| EBITDA Ratio | -6,231.56% | 0.00% | -1,918.09% | -1,305.74% | -716.54% | -691.18% | -2,811.71% | -3,181.22% | -939.87% | -340.52% | -1,611.71% | -624.63% | -994.23% | -1,312.61% | 0.00% | -139.57% | -164.16% | -149.86% |
| Operating Income | -16.63M | -29.31M | -49.69M | -31.11M | -14.00M | -15.79M | -14.23M | -14.27M | -9.89M | -6.67M | -3.84M | -6.67M | -9.33M | -9.65M | -4.59M | -1.93M | -1.87M | -1.67M |
| Operating Income Ratio | -7,392.89% | 0.00% | -2,085.19% | -1,312.15% | -854.88% | -782.36% | -3,204.28% | -3,622.84% | -1,043.57% | -360.13% | -1,873.17% | -662.07% | -730.19% | -1,856.25% | 0.00% | -163.71% | -189.00% | -185.79% |
| Total Other Income/Expenses | 1.19M | 0.00 | 184.00K | 7.90M | -2.44M | -1.81M | -1.88M | -1.87M | -764.00K | 41.00K | 174.00K | 469.00K | 3.65M | -2.49M | -1.49M | 20.42K | 0.00 | 0.00 |
| Income Before Tax | -15.44M | -29.31M | -50.30M | -23.21M | -16.44M | -17.60M | -16.11M | -16.14M | -10.66M | -6.63M | -3.67M | -6.20M | -5.62M | -12.10M | -6.08M | -1.91M | -1.87M | -1.67M |
| Income Before Tax Ratio | -6,863.56% | 0.00% | -2,110.95% | -979.04% | -1,003.91% | -872.00% | -3,627.93% | -4,096.19% | -1,124.16% | -357.91% | -1,788.29% | -615.49% | -440.34% | -2,327.44% | 0.00% | -161.97% | -189.00% | -185.79% |
| Income Tax Expense | 0.00 | -1.64M | 701.00K | 46.00K | 2.47M | -4.00K | 34.00K | 347.00K | -65.00K | -9.00K | 45.00K | 120.00K | -3.65M | 2.49M | 2.40K | 1.53K | 3.71K | 851.00 |
| Net Income | -24.91M | -29.31M | -51.01M | -23.26M | -18.92M | -17.59M | -16.11M | -14.53M | -9.76M | -6.63M | -3.67M | -6.20M | -5.68M | -12.14M | -6.08M | -1.91M | -1.87M | -1.67M |
| Net Income Ratio | -11,069.78% | 0.00% | -2,140.37% | -980.98% | -1,154.76% | -871.80% | -3,627.25% | -3,688.32% | -1,029.96% | -357.91% | -1,788.29% | -615.49% | -444.35% | -2,334.73% | 0.00% | -162.10% | -189.38% | -185.88% |
| EPS | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| EPS Diluted | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| Weighted Avg Shares Out | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
| Weighted Avg Shares Out (Dil) | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
iBio Reports Fiscal First Quarter 2025 Financial Results
Advanced myostatin program with dosing underway in non-human primate study Advanced myostatin program with dosing underway in non-human primate study
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming...
iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development
Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of cardiometabolic targets Life sciences industry veteran to lead strategic alliances for iBio's machine learning platform for antibody discovery and pipeline of...
iBio Closes Sale of Manufacturing Facility in Texas
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”),...
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a...
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.
iBio stock nearly tripled on Wednesday: here's why
Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.
iBio partners with AstralBio to develop obesity treatments using AI-driven platform
iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The...
Why Is iBio (IBIO) Stock Up 125% Today?
iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new...
Source: https://incomestatements.info
Category: Stock Reports